Literature DB >> 17131393

Total thyroidectomy for differentiated thyroid cancer.

Julie Ann Sosa1, Robert Udelsman.   

Abstract

There has been a long debate about the optimal surgical management of differentiated thyroid cancer. It has focused on the extent of thyroidectomy, with recommendations ranging from thyroid lobectomy to total thyroidectomy. There is no randomized prospective trial addressing this issue; such a trial would be prohibitive, since differentiated thyroid cancer has a good prognosis and a long natural history. Instead, there is heavy reliance on retrospective analyses, as well as consensus expert opinion and experience. We review this evidence, along with recent recommendations from several professional associations. We believe that total or near-total thyroidectomy followed by (131)I ablation and thyroid hormone suppression are most appropriate for the majority of patients with differentiated thyroid cancer, as retrospective analyses have shown that they reduce the risk of cancer recurrence, address the chance of multifocal intrathyroidal cancer, and facilitate use of surveillance scans and thyroglobulin monitoring for post-operative recurrence. This recommendation comes with the caveat that total thyroidectomy must be performed safely, since there is evidence that surgeon volume is associated with patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17131393     DOI: 10.1002/jso.20695

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  11 in total

1.  It sometimes happens: late tracheal rupture after total thyroidectomy.

Authors:  Luca Bertolaccini; Corrado Lauro; Roberto Priotto; Alberto Terzi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-01-09

2.  Local bupivacaine for postoperative pain management in thyroidectomized patients: A prospective and controlled clinical study.

Authors:  Ersin Gürkan Dumlu; Mehmet Tokaç; Haydar Öcal; Doğukan Durak; Halil Kara; Mehmet Kılıç; Abdussamed Yalçın
Journal:  Ulus Cerrahi Derg       Date:  2015-09-01

3.  Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer.

Authors:  Hari A Deshpande; Scott Gettinger; Julie Ann Sosa
Journal:  Core Evid       Date:  2010-06-15

4.  Follicular thyroid carcinoma invades venous rather than lymphatic vessels.

Authors:  Xiaoqi Lin; Bing Zhu; Yulin Liu; Jan F Silverman
Journal:  Diagn Pathol       Date:  2010-01-22       Impact factor: 2.644

5.  BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Authors:  Mingzhao Xing; Douglas Clark; Haixia Guan; Meiju Ji; Alan Dackiw; Kathryn A Carson; Matthew Kim; Anthony Tufaro; Paul Ladenson; Martha Zeiger; Ralph Tufano
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

6.  Thyroid cancer: burden of illness and management of disease.

Authors:  Rebecca L Brown; Jonas A de Souza; Ezra Ew Cohen
Journal:  J Cancer       Date:  2011-04-04       Impact factor: 4.207

7.  Minimally invasive follicular thyroid carcinomas: prognostic factors.

Authors:  Gustav Stenson; Inga-Lena Nilsson; Ninni Mu; Catharina Larsson; Catharina Ihre Lundgren; C Christofer Juhlin; Anders Höög; Jan Zedenius
Journal:  Endocrine       Date:  2016-02-08       Impact factor: 3.633

Review 8.  Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma.

Authors:  De-Tao Yin; Kun Yu; Run-Qing Lu; Xianghua Li; Jianhui Xu; Mengyuan Lei
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

9.  [Lymph node dissection in papillary and follicular thyroid cancer].

Authors:  C Vorländer; R H Lienenlüke; R A Wahl
Journal:  Chirurg       Date:  2008-06       Impact factor: 0.920

10.  The Effect of Levothyroxine Discontinuation Timing on Postoperative Hypothyroidism after Hemithyroidectomy for Papillary Thyroid Microcarcinoma.

Authors:  Tae Kwun Ha; Dong Wook Kim; Ha Kyoung Park; Jin Wook Baek; Yoo Jin Lee; Young Mi Park; Do Hun Kim; Soo Jin Jung; Ki Jung Ahn
Journal:  Int J Endocrinol       Date:  2016-05-11       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.